Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / ANO1

ANO1

Basics

Aliases:
This biomarker is also known as:
  • discovered on gastrointestinal stromal tumors protein 1,
  • TMEM16A,
  • transmembrane protein 16A,
  • DOG1,
  • Discovered on gastrointestinal stromal tumors protein 1,
  • Tumor-amplified and overexpressed sequence 2,
  • ORAOV2,
  • Oral cancer overexpressed protein 2,
  • transmembrane protein 16A (eight membrane-spanning domains),
  • FLJ10261,
  • tumor-amplified and overexpressed sequence 2,
  • anoctamin 1, calcium activated chloride channel,
  • anoctamin-1,
  • Transmembrane protein 16A,
  • TAOS2,
  • oral cancer overexpressed 2,

View in BioMuta

Description…

ANO1, or anoctamin-1, is a calcium-activated chloride channel gene overexpressed in many tumors. ANO1 is ubiquitously expressed in epithelia and is thought to be important in epithelial fluid transport.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: ANO1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

ANO1 is located within the 11q13 amplicon, one of the most frequently amplified chromosomal regions in human cancer. ANO1 is amplified and highly expressed in breast cancer cell lines and primary tumors.

Performance Comment

ANO1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.